

Patient Name TESTINGRNV,GTPMT POS	Patient ID SA00065672	Age 39	Gender F	Order # SA00065672
Ordering Phys CLIENT,CLIENT				DOB 01/01/1975
Client Order # SA00065672	Account Information			Report Notes
Collected 02/18/2014 06:00	C7028846-DLMP Rochester SDSC 2 - Client Support			
Printed 03/10/2014 13:52	Rochester, MN 55901			

Test	Flag	Results	Unit	Reference Value	Perform Site*
------	------	---------	------	-----------------	---------------

TPMT Genotype, B
RECEIVED: 02/19/2014 08:28 **REPORTED:** 02/19/2014 08:58

TPMT Genotype Result 1/2

MCR

This individual is heterozygous for a deficient or inactive TPMT allele (*2).

TPMT Interpretation

MCR

This patient is expected to have intermediate TPMT activity. Patients with intermediate TPMT activity can be treated with thiopurine drugs with fewer side effects by reducing the initial dose. Subsequent dose adjustments should be based on the degree of myelosuppression and according to published guidelines. Dosing guidance for thiopurines can be found at: CPIC guidelines <http://www.pharmgkb.org/gene/PA356>.

Since some adverse reactions to thiopurine drugs, including myelosuppression, are not explained by TPMT (Genbank # NM_000367.2), regular monitoring of complete blood count (CBC) and liver function tests is still essential.

This test detects TPMT*2, *3A, *3B, and *3C. If these alleles are not detected, the patient most likely has the *1/*1 genotype. There is a small residual risk that other rare alleles may be present which are not detected by this assay and which might affect the patients response to thiopurine drugs. This genotyping method will not distinguish between a heterozygous *3A and the very rare *3B/*3C, which is associated with poor (deficient) enzyme activity. Evaluation of enzyme activity is necessary to definitively identify this rare genotype (Order Mayo Test ID TPMT, secondary ID 80291, Published name: Thiopurine Methyltransferase (TPMT), Erythrocyte using the specimen requirements for this test).

Inhibitors:

Co-prescription of allopurinol might inhibit TPMT activity.

Drugs that have been shown to inhibit TPMT activity include: naproxen, ibuprofen, ketoprofen, furosemide, sulfasalazine, mesalamine, olsalazine, mefenamic acid, thiazide diuretics, and benzoic acid inhibitors.

If the patient has had an allogeneic blood or marrow transplant or a recent (i.e. less than 6 weeks from time of sample collection) heterologous blood transfusion these

Performing Site Legend on Last Page of Report

Patient Name TESTINGRNV,GTPMT POS	Collection Date and Time 02/18/2014 06:00	Report Status Final
Page 1 of 2		>> Continued on Next Page >>

* Report times for Mayo performed tests are CST/CDT

Patient Name TESTINGRNV,GTPMT POS	Patient ID SA00065672	Age 39	Gender F	Order # SA00065672
Ordering Phys CLIENT,CLIENT				DOB 01/01/1975
Client Order # SA00065672	Account Information			Report Notes
Collected 02/18/2014 06:00	C7028846-DLMP Rochester SDSC 2 - Client Support			
Printed 03/10/2014 13:52	Rochester, MN 55901			

Test	Flag	Results	Unit	Reference Value	Perform Site*
results may be inaccurate due to the presence of donor DNA. Laboratory developed test. Reviewed By: Linnea M. Baudhuin, Ph.D. See Below MCR					

* Performing Site:

MCR	Mayo Clinic Laboratories - Rochester Main Campus 200 First St SW Rochester, MN 55905	Lab Director:
-----	---	---------------

Patient Name TESTINGRNV,GTPMT POS	Collection Date and Time 02/18/2014 06:00	Report Status Final
Page 2 of 2		** End of Report **

* Report times for Mayo performed tests are CST/CDT